Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Makoto Maemondo(Miyagi Prefectural Hospital Organization), Toshihiro Nukiwa(Tohoku University), Hitoshi Miyazawa(Saitama Medical University), Koichi Hagiwara(Jichi Medical University), Akihiko Gemma(Nippon Medical School), Hiroshi Isobe, Kozo Yoshimori(Japan Anti Tuberculosis Association), Kunihiko Kobayashi(Saitama International Medical Center), Ichiro Kinoshita(Hokkaido University), Akira Inoue(Tohoku University Hospital), Toshiyuki Harada(Hokkaido hospital), Shoji Okinaga(Tohoku University), Satoshi Oizumi(Hokkaido University), Yasuo Saijo(Ho Chi Minh City International University), Shunichi Sugawara(Sendai Kousei Hospital), Masahiro Ando, Satoshi Morita(Kyoto University), Takashi Ogura(Kanagawa Cardiovascular and Respiratory Center), Yuka Fujita, Hirohisa Yoshizawa(Niigata University Medical and Dental Hospital), Tomoaki Tanaka(Saitama Medical University), Masao Harada(Shikoku Cancer Center), Haruto Hirano(Iwate Prefectural Central Hospital)
Cited by 5,568
Related Papers
A cross-population atlas of genetic associations for 220 human phenotypes
|Nature Genetics|2021|2.4k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
|Cancer Cell|2012|1.4k
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2005|953